Corporate Fact Sheet 2008

Management

Elizabeth Hutt
Chief Executive Officer

Nurith Kurn, Ph.D.
Chief Scientific Officer

Doug Amorese, Ph.D.
Vice President,
Research and Development

Garry Miyada, Ph.D.
Vice President,
Product Development

Sue Pandey, Ph.D.
Vice President,
Field Operations

Yan Zhang
Vice President,
Marketing

Board of Directors

James N. Wilson
Chairman of the Board

Jeff Bird, M.D. Ph.D.
Director

Elizabeth Dávila
Director

Michael Hunkapiller, Ph.D.
Alloy Ventures

Elizabeth Hutt
Chief Executive Officer

Nurith Kurn, Ph.D.
Chief Scientific Officer,
Co-founder

Major Investors

Alloy Ventures
www.alloyventures.com

Sutter Hill
www.shv.com

Radius Venture Partners
www.radiusventures.com

For more information on NuGEN's investors, please contact Nancy Pecota, Chief Financial Officer
npecota@nugeninc.com

Mission

To develop and commercialize products that position NuGEN as the industry leader for nucleic acid amplification in the discovery and clinical research markets.

Business Overview

NuGEN has commercialized a family of proprietary RNA amplification and labeling products and will continue to introduce solutions, independently and with partners, for the discovery and clinical research markets. Based upon the company's proprietary amplification and labeling technology, NuGEN's products change the manner in which life scientists recruit and utilize specimens for gene expression analysis. Sample size and quality requirements are significantly reduced, thus enabling the investigation of previously intractable specimens. Using NuGEN's powerful workflows, life scientists will perform more robust analysis, generate more reliable meaningful data, increase productivity, and achieve significant discoveries.

RNA expression analysis is an important research tool for improving the understanding of the molecular basis of disease, identifying drug targets, elucidating the effect of new drug compounds, and discovering novel biomarkers. Today, **NuGEN's products uniquely serve life science researchers** by allowing them to use significantly less input RNA, complete experiments more quickly, and generate results with improved reproducibility and sensitivity.

As gene expression analysis discoveries lead to new biomarkers for predicting disease risk and drug response, clinical diagnostic applications will become a reality. To meet this growing demand, NuGEN's solutions will enable clinical research laboratories to perform robust, high fidelity RNA amplification from challenging clinical specimens such as biopsies, laser capture micro-dissected tissue, Formalin Fixed Paraffin Embedded (FFPE), and whole blood samples. NuGEN, with its core technologies continues to significantly contribute to the high growth of clinically focused applications for RNA expression profiling, by providing unique solutions and access to new challenging clinical sample sources.

Ovation® System – RNA Amplification and Labeling Kits

NuGEN's Ribo-SPIA® technology represents the proprietary foundation for the Ovation System family of products. Ribo-SPIA technology provides a single, reliable, sensitive, rapid, and cost-effective amplification and labeling solution for gene expression analysis that is easily automatable. The Ovation System product family consists of kits designed for specific RNA amplification and labeling applications. In 2003, NuGEN launched its first amplification and labeling system for spotted arrays. Since then, many product and protocol introductions have followed to support every major expression analysis platform; Affymetrix GeneChip® 3' and Exon arrays, Agilent Dual Mode DNA gene expression arrays, Illumina Genome-Wide Expression BeadChips, as well as qPCR.

Ribo-SPIA® Technology for Gene Expression Analysis

NuGEN's research on high sensitivity amplification and detection technologies led to the development of Ribo-SPIA® RNA amplification technology.

Ribo-SPIA technology overcomes the limitations of alternative amplification methods and meets the growing demand for rapid, high fidelity RNA amplification for gene expression analysis regardless of starting RNA sample quantity and quality.

Until now, significant time, expense, and focus have gone into procuring samples of sufficient size to yield microgram quantities of RNA for gene expression studies. The Ovation product line requires only picograms of starting total RNA; reducing the need to collect large amounts of clinical samples. Furthermore, Ovation can provide access to the many biologically important specimens and homogeneous cell populations that cannot be obtained in large quantities, finally making these specimens accessible to investigators. The cDNA product generated by the Ovation System is the antisense (opposite sense) of the mRNA starting material; making the amplified product compatible with the standard probe set designs used with microarrays. Additionally the cDNA product can be used directly for quantitative PCR analysis, for validation of microarray results, and for archiving rare and complex samples.

Intellectual Property

NuGEN supports its product portfolio by pursuing patent protection for its core amplification technology platforms (SPIA® and Ribo-SPIA) and their applications as well as ancillary technologies that support these core technologies or otherwise provide a competitive advantage. NuGEN currently holds many issued U.S. patents and has over 60 patent applications pending in the U.S. and abroad.

The Ovation® System family of products are covered by one or more of U.S. Patent Nos. 6,692,918, 6,251,639, 6,946,251 and 7,354,717, and other issued and pending patents in the US and other countries.

Partnering Opportunities

NuGEN is actively establishing alliances for gene expression applications in the discovery, development, and clinical fields. NuGEN is also interested in pursuing alliances with qualified partners for:

- Co-marketing/co-promotion partnerships with gene expression platform companies (e.g. microarrays, microfluidics)
- Development and marketing collaborations to co-develop customized, integrated products for specific applications and analysis platforms
- Worldwide distribution of proprietary Ribo-SPIA reagents and kits for the clinical diagnostic market

Corporate Contact

Ericka Diaz
650.590.3600

NuGEN Technologies, Inc.
Headquarters USA:
821 Industrial Road,
Unit A, San Carlos,
CA 94070, U.S.A.
Tel: 888.654.6544
Fax: 888.296.6544
www.nugeninc.com